Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Viking Therapeutics (VKTX) yesterday and set a price target of $14. The company’s shares closed yesterday at $7.57, close to its 52-week low of $6.97.
According to TipRanks.com, Archila has 0 stars on 0-5 star ranking scale with an average return of -11.3% and a 26.3% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
Currently, the analyst consensus on Viking Therapeutics is a Strong Buy with an average price target of $22.33, a 195.0% upside from current levels. In a report issued on July 30, B.Riley FBR also reiterated a Buy rating on the stock with a $16 price target.
See today’s analyst top recommended stocks >>
Based on Viking Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.92 million. In comparison, last year the company had a GAAP net loss of $6.67 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company’s clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214.
